GlycoMimetics, Inc. (GLYC) Dividend History

GlycoMimetics, Inc. (GLYC) is a biopharmaceutical company focused on developing innovative glycomimetic drugs to treat cancers, infectious diseases, and inflammatory conditions. The company's research emphasizes targeting selectin proteins and other carbohydrate-mediated pathways to improve patient outcomes.

9708 Medical Center Drive, Rockville, MD, 20850
Phone: 240-243-1201
Website: https://www.glycomimetics.com

Dividend History

GlycoMimetics, Inc. currently does not pay dividends

Company News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, LRFC, RDW, GLYC on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating several companies for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders.

GlobeNewswire Inc.

Featured Companies: LRFC RDFN RDW
GlycoMimetics Shares Are Soaring Tuesday: Here's Why

GlycoMimetics announced a merger with Crescent Biopharma and secured $200 million in funding to advance its oncology pipeline, causing its stock to surge on Tuesday.

Benzinga
Penny Stock Traders Guide to Different Order Types

A short guide to the three main types of orders with penny stocks The post Penny Stock Traders Guide to Different Order Types appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PennyStocks

Featured Companies: LRHC SNTI
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?

GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research
GlycoMimetics (GLYC) Q2 2022 Earnings Call Transcript

GLYC earnings call for the period ending June 30, 2022.

The Motley Fool

Page data last updated 07/23/2025 21:19:39 UTC